These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 24634114)

  • 1. Effects of lovastatin on hepatic expression of the low-density lipoprotein receptor in nephrotic rats.
    Wei LX; Chen L; Wang WM; Zhang XH; Wu JB; Liang SF; Shu GY
    Genet Mol Res; 2014 Feb; 13(1):938-44. PubMed ID: 24634114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Astragalus mongholicus and Angelica sinensis compound alleviates nephrotic hyperlipidemia in rats.
    Li J; Yu L; Li N; Wang H
    Chin Med J (Engl); 2000 Apr; 113(4):310-4. PubMed ID: 11775225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome.
    Vaziri ND; Liang K
    Am J Nephrol; 2004; 24(6):606-13. PubMed ID: 15583480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic tissue sterol regulatory element binding protein 2 and low-density lipoprotein receptor in nephrotic syndrome.
    Kim CH; Kim HJ; Mitsuhashi M; Vaziri ND
    Metabolism; 2007 Oct; 56(10):1377-82. PubMed ID: 17884448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation.
    Ness GC; Zhao Z; Lopez D
    Arch Biochem Biophys; 1996 Jan; 325(2):242-8. PubMed ID: 8561503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism.
    Vega GL; Grundy SM
    Kidney Int; 1988 Jun; 33(6):1160-8. PubMed ID: 3165483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase unmask transcriptional regulation of hepatic low-density lipoprotein receptor gene expression by dietary cholesterol.
    Lopez D; Ness GC
    Arch Biochem Biophys; 1997 Aug; 344(1):215-9. PubMed ID: 9244400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 15-oxa-32-vinyl-lanost-8-ene-3 beta,32 diol on the expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase and low density lipoprotein receptor in rat liver.
    Ness GC; Lopez D; Chambers CM; Zhao Z; Beach DL; Ko SS; Trzaskos JM
    Arch Biochem Biophys; 1998 Sep; 357(2):259-64. PubMed ID: 9735166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome.
    Vaziri ND; Liang KH
    Circulation; 2004 Jul; 110(4):419-25. PubMed ID: 15262831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity of lovastatin in rats with experimentally induced nephrotic syndrome.
    Joven J; Vilella E; Camps J; Masana L; Turner PR; Simó JM; Villabona C
    Nephron; 1990; 56(4):399-404. PubMed ID: 2079999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of hepatic cholesterol metabolism in CETP/LDLr mice by cholesterol feeding and by drugs (cholestyramine and lovastatin) that lower plasma cholesterol.
    Harada LM; Carrilho AJ; Oliveira HC; Nakandakare ER; Quintão EC
    Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1209-15. PubMed ID: 17184503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism study of chitosan on lipid metabolism in hyperlipidemic rats.
    Xu G; Huang X; Qiu L; Wu J; Hu Y
    Asia Pac J Clin Nutr; 2007; 16 Suppl 1():313-7. PubMed ID: 17392126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypocholesterolemic effect of spirulina in patients with hyperlipidemic nephrotic syndrome.
    Samuels R; Mani UV; Iyer UM; Nayak US
    J Med Food; 2002; 5(2):91-6. PubMed ID: 12487756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effect of lovastatin on lipoprotein profile in patients with primary nephrotic syndrome.
    Prata MM; Nogueira AC; Pinto JR; Correia AM; Vicente O; Rodrigues MC; Miguel MJ
    Clin Nephrol; 1994 May; 41(5):277-83. PubMed ID: 8050207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of hepatic LDL receptor-related protein in nephrotic syndrome: response to statin therapy.
    Kim S; Kim CH; Vaziri ND
    Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E813-7. PubMed ID: 15585592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rutin on lipid profile in hypercholesterolaemic rats.
    Ziaee A; Zamansoltani F; Nassiri-Asl M; Abbasi E
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):253-8. PubMed ID: 19175365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of lovastatin on the development of adriamycin nephropathy in rats].
    Tesar V; Zima T; Poledne R; Stejskalová A; Tĕmínová J; Stípek S
    Sb Lek; 1995; 96(1):35-42. PubMed ID: 8711364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of primary mixed hyperlipidemia with lovastatin.
    Vega GL; Grundy SM
    Arch Intern Med; 1990 Jun; 150(6):1313-9. PubMed ID: 2353864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
    Castaño G; Menéndez R; Más R; Amor A; Fernández JL; González RL; Lezcay M; Alvarez E
    Int J Clin Pharmacol Res; 2002; 22(3-4):89-99. PubMed ID: 12837046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia.
    Aoki T; Yamazaki H; Suzuki H; Tamaki T; Sato F; Kitahara M; Saito Y
    Arzneimittelforschung; 2001; 51(3):197-203. PubMed ID: 11304935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.